Evidence supporting the use of: DHA (docosahexaeonic acid)
For the health condition: Convulsions

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

DHA (docosahexaenoic acid), an omega-3 long-chain polyunsaturated fatty acid, has garnered scientific interest for its role in neurological health, including potential effects on convulsions (seizures). DHA is a major structural component of neuronal membranes, influencing membrane fluidity, receptor function, and neurotransmission. Epidemiological and animal studies suggest that omega-3 fatty acids may have anticonvulsant properties. In animal models, DHA supplementation has demonstrated a capacity to reduce seizure susceptibility and severity, possibly through modulation of ion channels and anti-inflammatory effects. Some small clinical studies and case reports have explored DHA supplementation in individuals with epilepsy, reporting reduced seizure frequency in subsets of patients, particularly those with drug-resistant forms. However, these studies often have methodological limitations, such as small sample sizes, lack of blinding, or confounding from co-administration of other fatty acids. Systematic reviews and meta-analyses conclude that there is insufficient high-quality evidence to recommend DHA as a primary or adjunctive therapy for convulsions in humans. The American Epilepsy Society and similar organizations do not currently endorse DHA supplementation for seizure control outside of research settings. Overall, while there is a plausible biological rationale and preliminary data suggesting potential benefit, the clinical evidence remains limited and inconsistent. Thus, the use of DHA for convulsions should be considered experimental, and more rigorous human trials are needed to establish efficacy and safety.

More about DHA (docosahexaeonic acid)
More about Convulsions